Nova Scotia Health approaching goal of reduced surgical waitlist
In December of 2022, Karen Oldfield vowed before the legislature's health committee — first asking for a Bible to swear upon before crossing her heart in the absence of the Good Book — that the backlog would be reduced by 10,000 people by mid-2025. At the time, the list stood at about 22,000 people.
Such a decrease would bring the province in line with national benchmarks for surgical waitlists.
"I'm not going to hell," Oldfield joked with reporters Friday following an appearance on a panel at a Halifax Chamber of Commerce luncheon to discuss innovation in health care.
"We are 1,500 surgeries away from what we would consider to be an appropriate [waitlist]. With any luck, we will hit that this year."
Statistics released by Nova Scotia Health show the province's waitlist as of April 1 of this year was 15,769 people. That's down from 17,369 people the same time the year before, and 19,917 people as of April 1, 2023.
The procedures with the largest number of people waiting are cataract extraction (3,564), knee replacement (1,274) and hip replacement (783).
Oldfield said the progress comes down to the health authority's ability to make a plan and stick to it.
"There's no magic," she said. "It's focus and discipline to do it."
Although the health authority announced in 2023 a premium for doctors willing to work outside traditional hours in order to cut into the backlog, Oldfield said the biggest factor in making progress has been getting staffing levels back to where they needed to be coming out of the COVID-19 pandemic.
"We did lose a lot of staff. Not just because of COVID, but people — they burn out, they age out, they retire. So we've been through a period of resurgence."
Oldfield said she would like to see more surgeries happening during off-hours, but there needs to be a certain level of staffing to be able to make that work and take full advantage of available operating room time and equipment.
"When we have assets, you want to use your assets," she said. "And when they sit idle, that's not a good thing. So we still have lots of time across the province that these could be used."
MORE TOP STORIES
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
25 minutes ago
- The Hill
RFK Jr. attacks pediatric group after vaccine recommendations
Hours after the American Academy of Pediatrics (AAP) broke with Health and Human Services (HHS) Secretary Robert F. Kennedy Jr and recommended COVID-19 vaccines for all young children, he blasted the association as beholden to corporate interests. The AAP on Tuesday recommended all infants and children 6 months through 23 months get vaccinated against COVID-19 to help protect against serious illness. Kennedy responded in a post on social platform X, calling the group's recommendations 'corporate friendly' because AAP receives donations to its Friends of Children Fund from vaccine companies like Pfizer and Moderna, among others. The philanthropic fund backs projects supporting child health and equity. The health secretary said the organization should disclose 'its corporate entanglements … so that Americans may ask whether the AAP's recommendations reflect public health interest, or are, perhaps, just a pay-to-play scheme to promote commercial ambitions of AAP's Big Pharma benefactors.' Susan Kressly, AAP's president, in a statement said the group would welcome an opportunity to sit down with Kennedy to review the recommendations. 'This attack on the integrity of pediatricians is unfortunate, but it does not change the facts,' Kressly said. 'We are transparent about our funders, follow rigorous conflict-of-interest disclosures and maintain safeguards to ensure the integrity and independence of our guidance.' The AAP and HHS have been at odds for months, and tensions reached a head when Kennedy dismissed all the members of the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) and replaced them with his own handpicked representatives, including some outright vaccine skeptics. The AAP chose not to participate in the reconstituted panel's first meeting in June, calling it 'illegitimate.' Kennedy later excluded the fund along with other top medical organizations from working with the panel to research and help influence vaccination recommendations. Kennedy has long criticized the so-called medical establishment for conspiring to make Americans sick. His first ' Make America Healthy Again ' report accused doctors of being overly influenced by the pharmaceutical industry to overprescribe certain medications that don't treat the root causes of disease.
Boston Globe
an hour ago
- Boston Globe
Why COVID is spreading again this summer
Researchers have braced for an uptick. Though the virus is largely unpredictable — variants shape-shift and symptoms can change from one infection to the next — COVID cases have gone up every summer since the pandemic began. Around this time last year, there were higher levels of COVID in wastewater than there are currently; this appears to be, so far, a milder wave. As of June, when the CDC last updated its variant tracker, the COVID variant NB.1.8.1. — nicknamed 'Nimbus' — accounted for the most cases in the United States, around 43 percent. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up The variant does not appear to make people sicker than other recent strains of the virus, but it does have a few additional mutations that might make it more transmissible and better at evading the immune system's defenses, said Dr. Aubree Gordon, an infectious disease epidemiologist at the University of Michigan. Advertisement The latest data suggests that while we're not in a full-on surge, we are in a late summer upswing, said Dr. Ziyad Al-Aly, a senior clinical epidemiologist at Washington University in St. Louis. 'Very clearly, the numbers are going up,' he said. 'It's here.' Scientists point to a few reasons the virus reliably spreads each summer: Advertisement People spend time in air-conditioned spaces. Summer spikes may seem counterintuitive: People often spend more time outside when the weather's warm, and the virus has a much harder time circulating outdoors. But the heat also drives people inside to seek refuge in air-conditioned spaces with no windows open, leading to poor ventilation. The colder the environment, the longer the virus survives, and the easier COVID spreads, Al-Aly said. Summer travel and crowds fuel the spread. People travel more during the summer, cramming into airports and packing into trains. The Fourth of July holiday, in particular, creates a 'ripe breeding ground for COVID to run around,' said Dr. Davey Smith, an infectious disease specialist at the University of California, San Diego, similar to how infections tend to rise after Thanksgiving and Christmas. Even if people are outside at an event like a music festival, the virus can still spread in crowds. Infected people breathe out respiratory droplets and tiny particles of virus; when people wedge tightly enough together, they can inhale those contaminated droplets. Immunity to the virus can fade by summer. COVID, like many respiratory viruses, also rises in the winter. People who get COVID during the winter months will likely have good protection from reinfection for around four to six months, depending on how quickly new variants develop, Smith said. But by the time summer rolls around, immunity tends to wane, and people are susceptible to getting sick again. The same goes for people who get vaccinated in the fall or winter; their immunity dwindles, Al-Aly said, enabling a wave of new cases. Bottom line: If you feel sick, test. Advertisement COVID strikes in the summer more often than some other respiratory viruses with similar symptoms. If you're coughing and sniffling during summer, you may be more likely to have COVID than the flu or respiratory syncytial virus — and you should reach for a COVID test, Al-Aly said. The summer uptick underscores the importance of getting vaccinated, he added. But it's unclear currently how widely available updated COVID vaccines might be this year. The rising levels of COVID don't present a 'panic situation,' Al-Aly said, but people should 'be aware that numbers are now higher than they were a couple months ago.' This article originally appeared in
Yahoo
2 hours ago
- Yahoo
Novavax Strengthens Position with Vaccine Approval and Sanofi Partnership
Novavax, Inc. (NASDAQ:NVAX) is one of the 11 Best Short Squeeze Stocks to Buy Now. The company's non-mRNA COVID-19 vaccine is approved, strengthening its Sanofi partnership. A closeup of a vial of the biotechnology company's vaccines. Novavax, Inc. (NASDAQ:NVAX) is a biotechnology company focused on recombinant protein-based vaccines using nanoparticle and Matrix-M adjuvant technology. The Maryland-based company has an approved COVID-19 vaccine, Nuvaxovid, which is being commercialized globally through partnerships, including a major agreement with Sanofi. Currently, the company is expanding its product reach for emerging infectious disease prevention. On May 19, 2025, Novavax, Inc. (NASDAQ:NVAX) announced that it had received U.S. FDA Biologics License Application (BLA) approval for Nuvaxovid™, a recombinant protein-based, non-mRNA COVID-19 vaccine. The BLA approval triggered a $175 million milestone payment from Sanofi. Later, for select markets, Novavax, Inc. (NASDAQ:NVAX) has completed the transition of Nuvaxovid™ commercial leadership to Sanofi for the 2025-2026 COVID-19 vaccination season. By Q4 2025, the marketing authorization transfers to Sanofi for the U.S. and EU markets will be completed, which will result in an additional $50 million in combined milestones. Additionally, in June 2025, initial cohort data from a Phase 3 trial for Novavax's COVID-19-Influenza-Combination (CIC) and stand-alone influenza vaccine candidates showed significant immune responses, with T-cell responses numerically higher than the comparator Fluzone HD arm. With the results suggesting increased duration of protection, the company is discussing potential partnerships for these late-stage assets. Novavax, Inc. (NASDAQ:NVAX)'s 29.12% short float signals heavy bearish sentiment. With it, the company is up on the stage for a sharp rebound with slight positive market sentiment shifts. While we acknowledge the potential of NVAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 12 Best REIT Stocks to Buy Right Now and 10 Stocks with Huge Catalysts on the Horizon Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
